Effect of glucagon-like peptide 1 (GLP-1) based diabetes medication on blood flow velocity in persons without cerebrovascular disease.
Phase of Trial: Phase II
Latest Information Update: 17 May 2017
At a glance
- Drugs Exenatide (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Acronyms EGRABINS1
- 07 Jun 2017 Biomarkers information updated
- 06 Feb 2017 Status changed from recruiting to completed.
- 23 Aug 2016 Status changed from not yet recruiting to recruiting.